Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 Tablets in Combination With Anti-Tumor Therapy in Participants With Advanced Prostate Cancer

NCT07730580 is registered in ClinicalTrials.gov with Evopoint Biosciences Inc. as lead sponsor.

NCT NCT07730580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 Tablets in Combination With Anti-Tumor Therapy in Participants With Advanced Prostate Cancer
Lead sponsor
Evopoint Biosciences Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 13, 2026
Completion date
December 31, 2028
Enrollment
242 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer